Longevity blood testing has a credibility problem. The useful tests are often the least glamorous: lipids, glucose, kidney markers, liver markers, blood counts, and a small number of context-specific add-ons. The hard part is not ordering a larger panel. It is knowing whether a result is screening information, diagnostic evidence, risk stratification, or a monitoring signal.
The basic rule: a blood test is not a longevity score
A blood test can reveal risk, injury, deficiency, inflammation, or a treatment effect. It cannot certify biological age, prove that a routine is working, or collapse a person’s future health into one reassuring dashboard. Dr. Soren Hale’s lane is biomarkers, but the Topol-style caution matters here: clinical utility is the test of the test.
That means asking four questions before treating any marker as meaningful. What condition or risk does it relate to? How reliable is the measurement? Would a different result change a clinician’s decision? And is the marker being interpreted alongside age, symptoms, medication, family history, blood pressure, and other risks?
For longevity-minded adults, the most defensible blood tests are usually not exotic. They are the tests that help identify major causes of lost healthy years: atherosclerotic cardiovascular disease, diabetes, chronic kidney disease, anaemia, liver disease, and selected deficiencies. They matter because they sit close to clinical decisions. They still need interpretation.
Lipids: the cardiovascular panel with the strongest claim
If one blood-test category deserves first place, it is lipids. Cardiovascular disease remains a dominant cause of premature death, and lipid measurements are embedded in mainstream risk assessment. NICE guidance on cardiovascular risk recommends measuring total cholesterol and HDL cholesterol to estimate cardiovascular risk, and using a full lipid profile and family history when judging possible familial lipid disorders.
The standard lipid panel usually includes total cholesterol, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, and triglycerides. Non-HDL cholesterol is useful because it captures cholesterol carried by atherogenic particles beyond LDL alone. LDL cholesterol remains clinically central, especially for treatment targets and follow-up.
ApoB adds a sharper particle-counting lens. Each atherogenic lipoprotein particle carries one apolipoprotein B molecule, so ApoB approximates the number of particles capable of entering the artery wall. A 2025 European Heart Journal analysis indexed in PubMed describes ApoB concentration as reflecting the number of atherogenic lipoproteins and a key lipid risk marker. That does not mean everyone needs an ApoB test, or that ApoB replaces clinical judgement. It is most useful when standard cholesterol numbers and metabolic risk do not tell the same story.
Lipoprotein(a), or Lp(a), is different. It is largely genetically determined and usually changes little with lifestyle. Measuring it once can help identify inherited cardiovascular risk, especially with premature heart disease in the family. But a high Lp(a) result is not a diagnosis, and it should not be treated as a consumer badge. It is a risk marker to discuss with a clinician.
Glucose markers: diagnosis and monitoring are not the same
Glucose testing is another high-yield category, but it is often muddled by wellness language. Fasting plasma glucose, HbA1c, and sometimes an oral glucose tolerance test answer related but different questions. HbA1c estimates average glycaemic exposure over roughly two to three months, while fasting glucose is a narrower snapshot.
The distinction matters because diabetes diagnosis has formal criteria. Diabetes UK’s summary of WHO diagnostic criteria notes that an HbA1c of 48 mmol/mol, or 6.5%, is recommended as a diagnostic cut-off, while also warning that a lower HbA1c does not exclude diabetes diagnosed by glucose tests. In people without symptoms, confirmatory testing is needed.
For someone already diagnosed with type 2 diabetes, HbA1c becomes a monitoring tool rather than a screening curiosity. NICE guidance on type 2 diabetes frames HbA1c targets as individual decisions, with caution around hypoglycaemia, frailty, comorbidity, and reduced life expectancy. That is the opposite of the simple lower-is-always-better message common in longevity marketing.
Continuous glucose monitors can be valuable medical tools for some people, particularly those using insulin or at risk of hypoglycaemia. They are less clearly useful as general longevity devices for healthy adults. If a blood glucose result is unexpected, the next step is not a diet experiment based on one graph. It is confirmation and context.
Kidney markers: eGFR and albuminuria belong together
Kidney function is easy to overlook until it is materially impaired. Creatinine-based estimated glomerular filtration rate, or eGFR, is a routine blood-derived estimate of filtration. It becomes more informative when paired with urine albumin-to-creatinine ratio, because kidney risk is not captured by filtration alone.
The KDIGO 2024 chronic kidney disease guideline classifies CKD by cause, GFR category, and albuminuria category. That framework is useful for longevity discussions because it resists a common error: treating a single eGFR number as the whole kidney story. Age, muscle mass, hydration, recent illness, medications, and repeat measurements all affect interpretation.
Albuminuria is especially important in diabetes, hypertension, and cardiovascular risk. It can signal kidney damage even when eGFR appears acceptable. Conversely, a mildly reduced eGFR in an older adult may require repeat testing and clinical context before anyone labels it disease. The useful longevity move is not more frequent self-testing. It is making sure kidney results are interpreted as a pair, over time.
Full blood count: boring, broad, and often useful
A full blood count is not a fashionable longevity marker. It is a broad safety check. It measures red cells, white cells, platelets, haemoglobin, haematocrit, and red-cell size. MedlinePlus’s overview of the complete blood count describes it as a group of tests that can help monitor overall health and investigate anaemia, infection, immune disorders, and blood cancers.
For healthy ageing, the value is often in what it catches indirectly. Low haemoglobin can point toward iron deficiency, B12 or folate deficiency, chronic inflammation, kidney disease, gastrointestinal blood loss, or other causes. A high white-cell count may reflect infection or medication effects. Platelet abnormalities can be transient, but they can also point toward inflammatory, liver, haematological, or medication-related problems.
The limitation is equally important: abnormal does not always mean dangerous, and normal does not always mean clear. Menstruation, hydration, recent exercise, acute illness, medicines, and laboratory variation can all shift results. A full blood count is a starting point for questions, not a standalone verdict.
Liver blood tests: injury signals need context
Liver panels are frequently marketed as detox reassurance. That framing is poor medicine. Liver blood tests are better understood as signals of injury, bile flow, synthetic function, and broader metabolic stress, depending on the marker. ALT and AST can rise with liver injury, but AST is also found outside the liver. GGT and alkaline phosphatase can suggest bile-duct or alcohol-related patterns, but they are not specific on their own.
The NHS Specialist Pharmacy Service notes that liver blood tests can be unclear in isolation: abnormal results do not always indicate the extent of liver damage, results can be normal even in advanced liver disease, and some abnormalities are transient or unrelated to liver disease. That is the sentence to remember before over-interpreting a mildly raised ALT.
For longevity, liver markers matter because metabolic dysfunction-associated steatotic liver disease, alcohol-related harm, viral hepatitis, medication effects, and autoimmune disease can surface through routine testing. They also carry contraindication implications: some supplements and medicines can affect liver tests or be risky in liver disease. Anyone with substantial elevations, jaundice, dark urine, severe abdominal pain, confusion, or bleeding symptoms needs prompt medical assessment rather than lifestyle tinkering.
Inflammation and nutrient markers: useful only when the question is precise
High-sensitivity C-reactive protein, ferritin, B12, folate, vitamin D, thyroid-stimulating hormone, and urate can all be clinically useful. None should be treated as a generic longevity dashboard.
Hs-CRP is a nonspecific inflammation marker that may contribute to cardiovascular risk assessment in selected settings, but it rises with infection, injury, autoimmune disease, obesity, and many other conditions. Ferritin can reflect iron stores, but it is also an acute-phase reactant, so inflammation can raise it. B12 and folate testing is relevant when there is anaemia, neuropathy, dietary risk, malabsorption, medication exposure, or other clinical reason. Vitamin D testing can be appropriate in risk groups, but routine testing of everyone is a weaker proposition than treating clear deficiency risk sensibly under local guidance.
This is where longevity testing often loses discipline. The question should come first. A test ordered without a clinical question can still produce an abnormal result, and the result can lead to repeat tests, anxiety, cost, or unnecessary treatment.
What this means in practice
- Start with clinical context: age, sex, family history, symptoms, blood pressure, medicines, pregnancy status, menstrual status, and previous results change interpretation.
- Treat lipid testing, glucose markers, kidney markers, full blood count, and liver blood tests as the core blood-work categories with the clearest mainstream utility.
- Ask whether a result is being used for screening, diagnosis, risk stratification, or monitoring; the same marker can mean different things in each role.
- Repeat or confirm unexpected results before drawing conclusions, especially when illness, hard exercise, fasting, alcohol, supplements, or medication changes may have affected the sample.
- Be cautious with direct-to-consumer panels that bundle dozens of markers without explaining what decisions the results should support.
- Discuss abnormal, borderline, or confusing results with a qualified clinician, particularly if symptoms, pregnancy, chronic disease, or prescribed medicines are involved.
What we don’t know
The evidence is strongest when blood tests connect to established disease pathways and clinical decisions. It is weaker when tests are sold as biological-age scores, wellness readiness metrics, or proof that an intervention has slowed ageing. Some emerging biomarkers may become useful, but most still need validation against hard outcomes, not just correlations with age or lifestyle.
Reference ranges are another limitation. They describe expected values in a population or laboratory method; they are not always optimal targets for an individual. A result can be within range and still be worth watching in context, or outside range and still be transient. This is why trend, timing, and the reason for testing matter.
The blood tests that matter for longevity are not the ones that promise certainty. They are the ones that reveal risks clinicians already know how to interpret, confirm, and monitor. The panel is only useful if the question is clear.
Photo: National Cancer Institute on Unsplash.